supp.fit

Serrapeptase

7 benefits mapped to clinical evidence across supplements.

Dose per serving from products

103 products in our catalogue print how much Serrapeptase a serving holds.

Most common: 50 mg to 100 mg, 40% of 103 products.

Dose per servingProducts
2.5 mg or less
1
2.5 mg to 5 mg
7
5 mg to 10 mg
6
10 mg to 25 mg
9
25 mg to 50 mg
11
50 mg to 100 mg
41
100 mg to 250 mg
24
over 250 mg
4

Benefit Evidence

Pain/swelling down

Mucus clearance up

373 people

Swelling ↓; pain

Swelling ↓; +4.8mm

Swelling ↓; −4.7mm

373 people

Swelling/pain ↓; +7.5mm opening

Edema/symptoms ↓; 3-4d faster

333 people

Pain↓ 63%

Pain+swelling↓

Pain↓ vs placebo

233 people

Trismus +4.8–7.5 mm

Swelling -2 to -4.7 mm

Pain unchanged

140 people

Mouth opening +4.8-7.5 mm

Swelling -2 to -4.7 mm

140 people

Swelling, pain reduction

Mouth opening +4.8mm

140 people

Research sources

Illness recovery (3)
  1. [Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase]

    PubMed ID: 9091835

    Thrombophlebitis trial showed moderate symptomatic improvement (pain/edema), suggesting faster clinical resolution vs baseline.

  2. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo

    PubMed ID: 2257960

    RCT reported faster symptom improvement and earlier regression vs placebo (anti‑oedema and symptom speed).

  3. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Large post‑third‑molar trial showed earlier improvement in swelling/trismus vs placebo (objective measures).

Swelling relief (3)
  1. [Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase]

    PubMed ID: 9091835

    Thrombophlebitis RCT showed large percentage reductions in edema scores (−56.2%).

  2. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Large randomized trial found reduced facial swelling vs placebo on postoperative days 4–5 (objective measures).

  3. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo

    PubMed ID: 2257960

    Large RCT described anti‑oedema activity and earlier reduction in local swelling vs placebo.

Tissue repair (2)
  1. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Objective improvements in swelling/trismus post‑extraction imply faster postoperative recovery.

  2. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo

    PubMed ID: 2257960

    Large RCT reported earlier symptom regression and anti‑oedema effects consistent with faster clinical resolution.

Pain relief (2)
  1. [Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase]

    PubMed ID: 9091835

    Thrombophlebitis RCT reported marked spontaneous pain reduction (−63.3%).

  2. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo

    PubMed ID: 2257960

    Large RCT described faster symptom improvement; pain reductions implied though exact pain data not provided.

Joint comfort (1)
  1. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Significant improvement in interincisal distance (mouth opening) indicates reduced local stiffness/trismus.

Joint mobility (1)
  1. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Marked improvement in interincisal distance (mouth opening) demonstrates better local mobility after extraction.

Skin repair (1)
  1. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial

    PubMed ID: 33653320

    Objective reductions in facial swelling and improved mouth opening after extraction indicate improved local postoperative recovery.

Similar by evidence

Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.

Products with Serrapeptase

Search all

318 products whose verified label declares Serrapeptase — not every bottle that mentions it in a title.